Related Experiment Video
Updated: Jul 25, 2026
18:48
In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
Published on: August 12, 2017
14.7K
Corifollitropin alfa for poor responders patients, a prospective randomized study
F M Fusi1, L Zanga2, M Arnoldi2
1Division of Reproductive Endocrinology, ASST Papa Giovanni XXIII, Piazza OMS 1, 24127, Bergamo, Italy. ffusi@asst-pg23.it.
Reproductive Biology and Endocrinology : RB&E
|July 11, 2020
Summary
Corifollitropin alpha (CFA) in a long agonist protocol improved outcomes for poor responders undergoing IVF. This approach yielded more oocytes and higher pregnancy rates compared to other protocols, offering a valuable option for fertility treatment.
Area of Science:
- Reproductive Endocrinology
- In Vitro Fertilization (IVF)
Background:
- Poor ovarian response is a significant challenge in assisted reproductive technologies.
- Corifollitropin alpha (CFA) offers advantages over traditional gonadotropins due to its extended half-life and rapid FSH level achievement.
- Evaluating different CFA administration protocols is crucial for optimizing treatment for poor responders.
Purpose of the Study:
- To compare the efficacy of two corifollitropin alpha (CFA) protocols (long agonist vs. short antagonist) against a no-CFA protocol in poor responders undergoing IVF.
- To assess the impact of CFA on oocyte yield, pregnancy rates, and ongoing pregnancies.
Main Methods:
- Patients meeting criteria for poor ovarian response (low AFC, AMH, previous oocyte yield, or advanced age) were enrolled.
- Stimulation involved either a long agonist protocol with CFA, a short antagonist protocol with CFA, or a control group without CFA.
- Ovarian stimulation utilized recombinant FSH (rFSH), LH (rLH), or human menopausal gonadotropin (HMG).
Main Results:
- Both CFA protocols led to a significantly higher number of retrieved oocytes compared to the no-CFA group (p < 0.05).
- The long agonist CFA protocol showed a trend towards better oocyte yield and significantly higher pregnancy rates.
- Cumulative pregnancy rates were higher in CFA groups, attributed to increased cryopreserved blastocysts.
Conclusions:
- The long agonist protocol with CFA, rFSH, and rLH demonstrated superior outcomes in all assessed parameters for poor responders.
- While a short antagonist CFA protocol was less effective than the long agonist, it still outperformed the no-CFA group.
- A long agonist protocol utilizing CFA and recombinant gonadotropins presents a promising strategy for managing poor ovarian response in IVF.
More Related Videos
Related Concept Videos
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...